Literature DB >> 32399427

A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy.

Masatoshi Kudo1.   

Abstract

Entities:  

Year:  2020        PMID： 32399427      PMCID： PMC7206602          DOI： 10.1159/000505189

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   11.740


× No keyword cloud information.
  45 in total

Review 1.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.

Authors:  Napoleone Ferrara; Kenneth J Hillan; Hans-Peter Gerber; William Novotny
Journal:  Nat Rev Drug Discov       Date:  2004-05       Impact factor: 84.694

2.  Pembrolizumab for the Treatment of Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2019-04-29       Impact factor: 11.740

3.  Randomised trials with provision for early stopping for benefit (or harm): The impact on the estimated treatment effect.

Authors:  S D Walter; G H Guyatt; D Bassler; M Briel; T Ramsay; H D Han
Journal:  Stat Med       Date:  2019-03-19       Impact factor: 2.373

4.  Improved efficacy of dendritic cell-based immunotherapy by cutaneous laser illumination.

Authors:  Xinyuan Chen; Qiyan Zeng; Mei X Wu
Journal:  Clin Cancer Res       Date:  2012-03-05       Impact factor: 12.531

5.  A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2019-09-18       Impact factor: 11.740

6.  Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

Authors:  Andrew X Zhu; Richard S Finn; Julien Edeline; Stephane Cattan; Sadahisa Ogasawara; Daniel Palmer; Chris Verslype; Vittorina Zagonel; Laetitia Fartoux; Arndt Vogel; Debashis Sarker; Gontran Verset; Stephen L Chan; Jennifer Knox; Bruno Daniele; Andrea L Webber; Scot W Ebbinghaus; Junshui Ma; Abby B Siegel; Ann-Lii Cheng; Masatoshi Kudo
Journal:  Lancet Oncol       Date:  2018-06-03       Impact factor: 41.316

7.  Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells.

Authors:  D I Gabrilovich; H L Chen; K R Girgis; H T Cunningham; G M Meny; S Nadaf; D Kavanaugh; D P Carbone
Journal:  Nat Med       Date:  1996-10       Impact factor: 53.440

8.  Inhibition of ovarian cancer growth by a tumor-targeting peptide that binds eukaryotic translation initiation factor 4E.

Authors:  Song Yi Ko; Huifang Guo; Nicolas Barengo; Honami Naora
Journal:  Clin Cancer Res       Date:  2009-05-19       Impact factor: 12.531

9.  Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib.

Authors:  Takeshi Terashima; Tatsuya Yamashita; Noboru Takata; Hidetoshi Nakagawa; Tadashi Toyama; Kuniaki Arai; Kazuya Kitamura; Taro Yamashita; Yoshio Sakai; Eishiro Mizukoshi; Masao Honda; Shuichi Kaneko
Journal:  Hepatol Res       Date:  2015-11-02       Impact factor: 4.288

10.  Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma.

Authors:  Sergei Kusmartsev; Evgeniy Eruslanov; Hubert Kübler; Timothy Tseng; Yoshihisa Sakai; Zhen Su; Sergei Kaliberov; Axel Heiser; Charles Rosser; Philip Dahm; Dietmar Siemann; Johannes Vieweg
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422
View more
  16 in total

1.  Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2021-02-15       Impact factor: 11.740

2.  Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes.

Authors:  Tania Afroj; Atsushi Mitsuhashi; Hirokazu Ogino; Atsuro Saijo; Kenji Otsuka; Hiroto Yoneda; Makoto Tobiume; Na Thi Nguyen; Hisatsugu Goto; Kazuya Koyama; Masamichi Sugimoto; Osamu Kondoh; Hiroshi Nokihara; Yasuhiko Nishioka
Journal:  J Immunol       Date:  2021-01-27       Impact factor: 5.422

Review 3.  Breaking the niche: multidimensional nanotherapeutics for tumor microenvironment modulation.

Authors:  K Laxmi Swetha; Kavya Sree Maravajjala; Shyh-Dar Li; Manu Smriti Singh; Aniruddha Roy
Journal:  Drug Deliv Transl Res       Date:  2022-06-13       Impact factor: 4.617

4.  Initial Experience of Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma in Clinical Practice.

Authors:  Teiji Kuzuya; Naoto Kawabe; Senju Hashimoto; Ryoji Miyahara; Takuji Nakano; Kazunori Nakaoka; Hiroyuki Tanaka; Yohei Miyachi; Arisa Mii; Yoshinao Tanahashi; Yutaro Kato; Atsushi Sugioka; Yoshiki Hirooka
Journal:  Cancer Diagn Progn       Date:  2021-05-03

5.  Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2).

Authors:  Masatoshi Kudo; Richard S Finn; Manabu Morimoto; Kun-Ming Rau; Masafumi Ikeda; Chia-Jui Yen; Peter R Galle; Josep M Llovet; Bruno Daniele; Ho Yeong Lim; David W McIlwain; Reigetsu Yoshikawa; Kenichi Nakamura; Kun Liang; Chunxiao Wang; Paolo Abada; Ryan C Widau; Andrew X Zhu
Journal:  Liver Cancer       Date:  2021-07-12       Impact factor: 11.740

6.  Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

Authors:  Alessandro Rizzo; Angela Dalia Ricci; Giovanni Brandi
Journal:  Liver Cancer       Date:  2021-12-08       Impact factor: 12.430

7.  Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2022-02-18       Impact factor: 12.430

Review 8.  Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.

Authors:  Alphonse E Sirica; Mario Strazzabosco; Massimiliano Cadamuro
Journal:  Adv Cancer Res       Date:  2020-12-09       Impact factor: 6.242

9.  A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2021-10-12       Impact factor: 11.740

Review 10.  Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?

Authors:  Ti Zhang; Philippe Merle; Huaqi Wang; Haitao Zhao; Masatoshi Kudo
Journal:  Hepatobiliary Surg Nutr       Date:  2021-04       Impact factor: 8.265
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.